NoNO Inc. is a clinical-stage biotherapeutics company dedicated to the research, development and commercialization of pharmaceuticals for the treatment of common health disorders with unmet needs, including stroke, traumatic brain injury, and pain. Its lead compound, NA-1, is entering into pivotal trials in Canada and the US in stroke and stroke-related indications.